Beam Therapeutics: $850.7M cash, pipeline progress, 2025 catalysts detailed

Beam Therapeutics Inc.

Preliminary cash, equivalents and marketable securities of $850.7M as of Dec 31, 2024; runway now into 2027 including BEAM-101 commercial readiness.
More than 40 adult SCD patients enrolled in BEACON trial; Beam expects to dose 30 patients and present updated data by mid-2025.
Initial Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency expected in first half 2025.
BEAM-301 Phase 1/2 trial in GSD1a: first site active, dosing to commence in early 2025.
ESCAPE nongenotoxic conditioning IND-enabling studies underway; BEAM-103 healthy volunteer study expected by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.